Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

Measles Virus Defective Interfering RNAs Are Generated Frequently and Early in the Absence of C Protein and Can Be Destabilized by Adenosine Deaminase Acting on RNA-1-Like Hypermutations. J Virol (2015) 0.81

Rescue of a Plant Negative-Strand RNA Virus from Cloned cDNA: Insights into Enveloped Plant Virus Movement and Morphogenesis. PLoS Pathog (2015) 0.80

One-Health: A Safe, Efficient Dual-use Vaccine for Humans and Animals against MERS-CoV and Rabies Virus. J Virol (2016) 0.79

A recombinant rabies virus carrying GFP between N and P affects viral transcription in vitro. Virus Genes (2016) 0.78

Marburg Virus Reverse Genetics Systems. Viruses (2016) 0.75

Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential. Viruses (2016) 0.75

Efficient and Robust Paramyxoviridae Reverse Genetics Systems. mSphere (2017) 0.75

New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71

Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics (2006) 14.96

Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A (1981) 12.00

Amplification, expression, and packaging of foreign gene by influenza virus. Cell (1989) 11.21

Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res (2011) 10.82

Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08

Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol (1999) 8.66

Infectious rabies viruses from cloned cDNA. EMBO J (1994) 8.35

Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87

Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A (1995) 6.95

Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A (1995) 6.51

Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol (1987) 6.13

SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07

Oncolytic virotherapy. Nat Biotechnol (2012) 5.79

Infectious defective interfering particles of VSV from transcripts of a cDNA clone. Cell (1992) 5.72

Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell (1981) 5.38

The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73

Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J Virol (1994) 4.10

The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol (1996) 3.89

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86

Rescue of a foreign gene by Sendai virus. Proc Natl Acad Sci U S A (1991) 3.85

Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79

A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J (1995) 3.63

Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology (1997) 3.58

Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50

Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47

Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells (1996) 3.41

QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature (1978) 3.11

Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science (2001) 3.08

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol (1998) 3.07

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01

Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94

Measles virus spread and pathogenesis in genetically modified mice. J Virol (1998) 2.84

Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc (2014) 2.73

The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J (1997) 2.71

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67

Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67

History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51

Rescue of rinderpest virus from cloned cDNA. J Virol (1997) 2.44

Rabies as a transneuronal tracer of circuits in the central nervous system. J Neurosci Methods (2000) 2.44

Transcription and replication of nonsegmented negative-strand RNA viruses. Curr Top Microbiol Immunol (2004) 2.41

Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40

Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A (1998) 2.31

An infectious clone of human parainfluenza virus type 3. J Virol (1997) 2.28

Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest (2008) 2.21

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19

Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol (2005) 2.18

Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J Virol (2005) 2.17

Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J Virol (2003) 2.10

Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10

Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol (2005) 2.09

Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06

Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology (1999) 2.03

Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol (2008) 1.96

Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA. Virology (1993) 1.91

VSV-tumor selective replication and protein translation. Oncogene (2005) 1.88

Sequential phosphorylation of the phosphoprotein of vesicular stomatitis virus by cellular and viral protein kinases is essential for transcription activation. J Virol (1992) 1.88

Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A (2004) 1.84

Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology (2004) 1.81

Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog (2011) 1.80

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80

Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology (2006) 1.80

Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A (1996) 1.72

New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2013) 1.72

Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68

Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines (2014) 1.67

Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol (2006) 1.67

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67

Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66

Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog (2010) 1.63

Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc Natl Acad Sci U S A (2005) 1.61

A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60

Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol (2005) 1.58

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58

Measles virus for cancer therapy. Curr Top Microbiol Immunol (2009) 1.56

Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J Virol (2006) 1.54

The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol (2013) 1.54

Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53

Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol (1999) 1.50

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol (2002) 1.47

Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46

Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44

Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J Virol (2003) 1.44

Reverse genetics of mononegavirales. Curr Top Microbiol Immunol (2004) 1.44

Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology (2001) 1.42

Regression of Burkitt's lymphoma in association with measles infection. Lancet (1971) 1.41

Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci U S A (2004) 1.41

Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res (2007) 1.41

Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol (2008) 1.36

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J Virol (2002) 1.36

A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol (2007) 1.34

Nyamanini and midway viruses define a novel taxon of RNA viruses in the order Mononegavirales. J Virol (2009) 1.33

Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). J Virol (2009) 1.32

Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol (2000) 1.31

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol (2004) 1.29

Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol (2003) 1.29

The regulation of type I interferon production by paramyxoviruses. J Interferon Cytokine Res (2009) 1.27

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27